Compare LQDT & NEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LQDT | NEO |
|---|---|---|
| Founded | 1999 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Precision Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.2B |
| IPO Year | 2005 | 2008 |
| Metric | LQDT | NEO |
|---|---|---|
| Price | $38.47 | $13.95 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 8 |
| Target Price | ★ $40.00 | $13.38 |
| AVG Volume (30 Days) | 154.6K | ★ 2.9M |
| Earning Date | 05-07-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 38.10 | N/A |
| EPS | ★ 0.46 | N/A |
| Revenue | ★ $476,669,000.00 | N/A |
| Revenue This Year | N/A | $10.63 |
| Revenue Next Year | N/A | $9.73 |
| P/E Ratio | $82.91 | ★ N/A |
| Revenue Growth | ★ 31.20 | N/A |
| 52 Week Low | $21.67 | $4.72 |
| 52 Week High | $39.55 | $13.88 |
| Indicator | LQDT | NEO |
|---|---|---|
| Relative Strength Index (RSI) | 61.53 | 78.61 |
| Support Level | $30.06 | $11.49 |
| Resistance Level | $38.63 | N/A |
| Average True Range (ATR) | 1.07 | 0.65 |
| MACD | 0.02 | 0.24 |
| Stochastic Oscillator | 70.85 | 94.98 |
Liquidity Services Inc is an online auction marketplace. It manages and sells inventory and equipment for business and government clients by operating a network of e-commerce marketplaces that enable buyers and sellers to transact in an efficient, automated environment offering across different product categories. The company has four reportable segments: GovDeals, Retail Supply Chain Group (RSCG), and Machinio & Software Solutions. It generates majority of its revenue from Retail Supply Chain Group (RSCG) segment which consists of marketplaces that enable corporations located in the United States and Canada to sell excess, returned, and overstocked consumer goods. Geographically, a substantial portion the company's revenue is generated from its business in United States.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.